Price2.06%   -0.02

Aridis Pharmaceuticals (ARDS) Latest News

Nov-22-22 09:10AM Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious DiseasesGlobeNewswire Inc.
Nov-21-22 07:55AM Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research
Nov-15-22 07:45AM Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research
Oct-12-22 12:16PM DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis StudyZacks Investment Research
12:03PM Albireo (ALBO) Up on Results From Alagille Syndrome StudyZacks Investment Research
Oct-11-22 05:32AM scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA ApprovalZacks Investment Research
11:49AM Iovance (IOVA) Doses First Patient in TIL Cancer Therapy StudyZacks Investment Research
Sep-28-22 01:13AM Avidity (RNA) Down on Partial Hold of Myotonic Dystrophy StudyZacks Investment Research
01:11AM Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study SizeZacks Investment Research
Sep-27-22 12:35PM 9 Meters (NMTR) Up on Results From Bowel Syndrome CandidateZacks Investment Research
06:29AM Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving PremarketBenzinga
Sep-27-22 05:15AM Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From YesterdayBenzinga
Sep-23-22 10:57AM DBV Technologies' (DBVT) Peanut Allergy Study on Partial HoldZacks Investment Research
Sep-21-22 11:39AM Wave Therapeutics (WVE) Up on Update From Huntington's StudyZacks Investment Research
Sep-19-22 12:15PM Intellia (NTLA) Reports Positive Results for CRISPR CandidatesZacks Investment Research
11:58AM bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALDZacks Investment Research
Aug-23-22 06:11AM Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From YesterdayBenzinga
Aug-22-22 01:02AM Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday's Mid-Day SessionBenzinga
Aug-16-22 05:25AM Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research
Aug-10-22 05:15AM BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research
Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.
Cap:    |  Volume (24h):